List view / Grid view
11 May 2021 | By PerkinElmer
Get the Big Picture and listen to Pharma thought leaders how they view CETSA® and its impact on their Drug Discovery.
Researchers have produced a computational simulation of the SARS-CoV-2 Spike protein, finding spots that glycans do not cover.
Researchers say that inhibiting NLRP3 with Dapansutrile could be an effective strategy to prevent melanoma tumour growth.
Studying the mouse gene Ophn1, researchers have found its removal causes stressed behaviours, also identifying three ways to reverse this effect.
A new compound can inhibit the build-up of plaque in arteries and prevent atherosclerosis, researchers have shown.
High IFN signalling in pancreatic tumours are sensitive to NAMPT inhibitors which block a pathway in NAD synthesis, presenting a drug target.
The drug combination of difluoromethylornithine and AMXT 1501 has shown success against Diffuse Intrinsic Pontine Glioma in animal models.
A study has shown that inhibiting the enzyme PRMT5 can suppress the growth of glioblastoma cells in pre-clinical studies.
A team has shown that STING activation is a new molecular target in the fight against graft-versus-host disease (GVHD).
Researchers studying SARS-CoV-2 at the individual cellular level have made four major discoveries about early infection from the coronavirus.
Researchers have found a druggable insulin inhibitory receptor named inceptor that could provide a drug target for diabetes.
Researchers have identified a new compound that improved responses to insulin and treated diabetes in obese mouse models.
Researchers have discovered that giving L-tyrosine and PCS to mice prevents lung inflammation and an allergic asthma response.
A team has developed a new way to discover peptide therapeutics that inhibit HDAC enzymes and are effective against cancer.
A team has found that their drug Molnupiravir (MK-4482/EIDD-2801) acts as an antiviral against SARS-CoV-2 in pre-clinical studies.
